300 Vials Per Minute: The Pace of Progress for Catalent

Posted: Updated:
A Catalent employee inspects a vial. A Catalent employee inspects a vial.

Just 18 months after entering Indiana’s life sciences landscape, Catalent says the “red hot” biologics sector is driving the company’s repeated large investments in Bloomington. Catalent, a contract development and manufacturing organization, does business with 41 of the top 50 biotechnology companies globally. As one of Catalent’s two nerve centers for biologics, the Bloomington site is growing at a breathtaking pace; Catalent has announced $114 million worth of investments in the operation during recent months, and executives believe there could be more.

“Our site in Bloomington may require even further investment in future years to keep up with ongoing demand,” says Bernie Clark, vice president of marketing and strategy for biologics and specialty drug delivery at Catalent.

The global company, based in New Jersey, generated $2.5 billion in annual revenue in fiscal 2018. Clark says biologics is one of the fastest growing markets in pharmaceuticals and drug development, and the Bloomington facility—which Catalent acquired from homegrown Cook Pharmica in 2017—focuses solely on this cutting-edge area of medicine.

Biologics—such as vaccines, gene therapy and tissues—demand state-of-the-art technology due to their highly sensitive and complex nature. Unlike conventional drugs with simpler structures that are produced by chemical reaction, biologics may be living organisms, such as cells and tissues.  

“[Biologics] are not your typical over-the-counter tablet; these are very advanced medicines, typically focused on difficult-to-treat diseases and illnesses, ranging from cancer to cardiovascular and infectious disease,” says Clark.  

Noting “there weren’t too many facilities quite like Bloomington” in the U.S., company leaders knew the high-tech operation would be up to the task when it acquired the location from Cook Pharmica.

“At Bloomington, in particular, we work on some of the most innovative molecules, starting with cell line development,” says Clark. “We help our customers grow products inside bioreactors at high volumes before taking the purified byproducts of those cells and filling them into liquid dose forms—sterile injectables, such as vials and syringes—and finally, packaging and labeling them for distribution to patients around the globe.”

Catalent recently announced it’s pumping $100 million into the plant to meet growing demand for biologics. The plans come on the heels of an earlier announcement to invest $14 million to ramp up packaging capabilities. A new high-speed line will fill 300 vials per minute, as well as a syringe/cartridge line that will operate at the same mind-boggling pace.

The increased volume is needed for the growing operation; in the 18 months since Catalent acquired the facility, it has expanded production from 12 commercial products to 20—a 66 percent increase.

 “More than capital, people are fundamental to making that growth a success,” says Clark. “We have dozens of job openings today, and we’ll be hiring hundreds in the coming years to ramp up our operations and deliver for our customers.”

Catalent believes Bloomington’s pocket of life sciences companies, plus the proximity of Indiana University and Indianapolis, will meet its appetite for workers. Additionally, the state’s talent and workforce development initiative Ascend Indiana is working with Catalent and a handful of higher education partners to launch a project that will expand the pool of line operators for the Bloomington facility.

“To fill the magnitude of positions we’ll have open in the coming years, it’s going to take employees of all skill levels and backgrounds, from packaging and operations to lab science, to quality and engineering—across the board,” says Clark.

Of the seven U.S. facilities that comprise its biologic division, Bloomington is one of only two getting a $100 million dose of capital—the perfect medicine, says Catalent, to support the boom in biologics.

Clark says several factors are contributing to the “red hot” nature of the biologics sector.
Clark says production at the Bloomington facility relies on high-tech bioreactors.
  • Perspectives

    • Market Caps: What's in Your Portfolio?

      Investors understand the importance of having a proper balance of large-, mid-, and small-cap companies in their stock portfolios. Unfortunately, there are no strict rules followed by index funds when categorizing by company size. When you "check under the hood" of your portfolio, you may discover you’re taking more (or less) risk than you intended! What Is Market Cap? Market capitalization, or market cap, is a term used to represent the size of a company.

    More

Subscribe

Name:
Company Name:
Email:
Confirm Email:
HTML
INside Edge
Morning Briefing
BigWigs & New Gigs
Life Sciences Indiana
Indiana Connections
INPower
Subscribe
Unsubscribe

Events



  • Most Popular Stories

    • Fishers Among Finalists For National Prize

      The city of Fishers is one of 12 finalists for the Robert Wood Johnson Foundation Culture of Health Prize. The award honors "communities that are bringing partners together around a shared commitment to health, opportunity, and equity."

    • (Image of planed West Lake Corridor Expansion of the South Shore commuter rail line provided by the Northwest Indiana Regional Development Authority.)

      South Shore Extension Moves Closer to Federal Funding

      The South Shore Line West Lake Corridor is a step closer to up to $440 million in federal funding, thanks to a positive project rating from the Federal Transit Administration. The "medium-high" rating means the project, which involves the extension of the South Shore Line between Dyer and Hammond, is eligible for funding to cover a large portion of the more than $700 million project. The rating came from the FTA's Fiscal Year 2020 Annual Report on Funding Recommendations...

    • (photo courtesy of our partners at The Times of Northwest Indiana)

      Indiana Leads U.S. Steel Production

      Indiana once again led the nation in steel production in 2018. Jake Murphy with the American Iron and Steel Institute tells our partners at The Times of Northwest Indiana steel mills throughout the state made 26.7 million net tons of steel last year, up from 24.1 million in 2017. 

    • Hanna believes crews could begin "turning dirt" in 2020.

      Hanna: South Shore Project Hits 'Major, Major Milestone'

      The president of the Northwest Indiana Regional Development Authority says the South Shore Line West Lake Corridor project will create a crucial "Hoosier gateway in Chicago." The more than $700 million project has received a positive project rating from the Federal Transit Administration, putting it a step closer to up to $440 million in federal funding. Bill Hanna says the rail extension will help Hoosier workers connect to jobs in Chicago that often pay more...

    • More Families Earn Hoosier Homestead Awards

      More than 50 families from throughout the state have been recognized for operating longstanding farms. Lieutenant Governor Suzanne Crouch and State Department of Agriculture Director Bruce Kettler have presented the latest Hoosier Homestead Awards, recognizing farms owned by the same family for more than 100 consecutive years.